These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 25294113

  • 1. Innovative therapeutic approach: sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome.
    Mussoni MP, Veneziano FA, Boetti L, Tassi C, Calisesi C, Nucci S, Rigotti A, Panzini I, Ardissino G.
    Transfus Apher Sci; 2014 Oct; 51(2):134-6. PubMed ID: 25294113
    [Abstract] [Full Text] [Related]

  • 2. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A.
    J Med Case Rep; 2015 Apr 29; 9():92. PubMed ID: 25925370
    [Abstract] [Full Text] [Related]

  • 3. Eculizumab for atypical hemolytic uremic syndrome in pregnancy.
    Ardissino G, Wally Ossola M, Maria Baffero G, Rigotti A, Cugno M.
    Obstet Gynecol; 2013 Aug 29; 122(2 Pt 2):487-489. PubMed ID: 23884270
    [Abstract] [Full Text] [Related]

  • 4. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.
    Ther Apher Dial; 2018 Apr 29; 22(2):178-188. PubMed ID: 29250893
    [Abstract] [Full Text] [Related]

  • 5. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
    Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G.
    Am J Case Rep; 2019 Oct 04; 20():1460-1465. PubMed ID: 31582717
    [Abstract] [Full Text] [Related]

  • 6. Pregnancy-associated atypical hemolytic uremic syndrome. Case report.
    Barrera-Hoffmann C, Mariaca-Ortíz Y, Ruiz-Villa JG, Cuevas-Cruz LE, López-Mendoza MDR, Briones-Garduño JC.
    J Obstet Gynaecol Res; 2024 Jul 04; 50(7):1268-1272. PubMed ID: 38720638
    [Abstract] [Full Text] [Related]

  • 7. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.
    Am J Kidney Dis; 2015 Aug 04; 66(2):331-6. PubMed ID: 26015278
    [Abstract] [Full Text] [Related]

  • 8. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D, Crowther B, Arar M, Assanasen C.
    Pediatr Transplant; 2014 Sep 04; 18(6):E185-9. PubMed ID: 24931815
    [Abstract] [Full Text] [Related]

  • 9. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.
    Transplant Proc; 2012 Dec 04; 44(10):3037-40. PubMed ID: 23195022
    [Abstract] [Full Text] [Related]

  • 10. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K, Seeman T.
    Transplant Proc; 2018 Apr 04; 50(3):967-970. PubMed ID: 29661469
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review.
    Gupta M, Govindappagari S, Burwick RM.
    Obstet Gynecol; 2020 Jan 04; 135(1):46-58. PubMed ID: 31809447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK, Kıhtır HS, Goknar N, Ersoy M, Akcay N, Sevketoglu E.
    Pediatr Nephrol; 2018 Jun 04; 33(6):1093-1096. PubMed ID: 29558000
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
    Toyoda H, Wada H, Miyata T, Amano K, Kihira K, Iwamoto S, Hirayama M, Komada Y.
    J Pediatr Hematol Oncol; 2016 Apr 04; 38(3):e137-9. PubMed ID: 26840081
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.